A citation-based method for searching scientific literature

Jie Xu, Li-Juan Chen, Shuang-Shuang Yang, Yan Sun, Wen Wu, Yuan-Fang Liu, Ji Xu, Yan Zhuang, Wu Zhang, Xiang-Qin Weng, Jing Wu, Yan Wang, Jin Wang, Hua Yan, Wen-Bin Xu, Hua Jiang, Juan Du, Xiao-Yi Ding, Biao Li, Jun-Min Li, Wei-Jun Fu, Jiang Zhu, Li Zhu, Zhu Chen, Xiao-Hu Frank Fan, Jian Hou, Jian-Yong Li, Jian-Qing Mi, Sai-Juan Chen. Proc Natl Acad Sci U S A 2019
Times Cited: 166







List of co-cited articles
1160 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma.
Noopur Raje, Jesus Berdeja, Yi Lin, David Siegel, Sundar Jagannath, Deepu Madduri, Michaela Liedtke, Jacalyn Rosenblatt, Marcela V Maus, Ashley Turka,[...]. N Engl J Med 2019
649
72

T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma.
Jennifer N Brudno, Irina Maric, Steven D Hartman, Jeremy J Rose, Michael Wang, Norris Lam, Maryalice Stetler-Stevenson, Dalia Salem, Constance Yuan, Steven Pavletic,[...]. J Clin Oncol 2018
369
63

B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma.
Adam D Cohen, Alfred L Garfall, Edward A Stadtmauer, J Joseph Melenhorst, Simon F Lacey, Eric Lancaster, Dan T Vogl, Brendan M Weiss, Karen Dengel, Annemarie Nelson,[...]. J Clin Invest 2019
304
57

A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma.
Wan-Hong Zhao, Jie Liu, Bai-Yan Wang, Yin-Xia Chen, Xing-Mei Cao, Yun Yang, Yi-Lin Zhang, Fang-Xia Wang, Peng-Yu Zhang, Bo Lei,[...]. J Hematol Oncol 2018
241
50

T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma.
Syed Abbas Ali, Victoria Shi, Irina Maric, Michael Wang, David F Stroncek, Jeremy J Rose, Jennifer N Brudno, Maryalice Stetler-Stevenson, Steven A Feldman, Brenna G Hansen,[...]. Blood 2016
463
40

A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial.
Zhiling Yan, Jiang Cao, Hai Cheng, Jianlin Qiao, Huanxin Zhang, Ying Wang, Ming Shi, Jianping Lan, Xiaoming Fei, Lai Jin,[...]. Lancet Haematol 2019
136
36

Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.
Nikhil C Munshi, Larry D Anderson, Nina Shah, Deepu Madduri, Jesús Berdeja, Sagar Lonial, Noopur Raje, Yi Lin, David Siegel, Albert Oriol,[...]. N Engl J Med 2021
266
32

B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma.
Robert O Carpenter, Moses O Evbuomwan, Stefania Pittaluga, Jeremy J Rose, Mark Raffeld, Shicheng Yang, Ronald E Gress, Frances T Hakim, James N Kochenderfer. Clin Cancer Res 2013
372
30

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.
Sattva S Neelapu, Frederick L Locke, Nancy L Bartlett, Lazaros J Lekakis, David B Miklos, Caron A Jacobson, Ira Braunschweig, Olalekan O Oluwole, Tanya Siddiqi, Yi Lin,[...]. N Engl J Med 2017
30

Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia.
Shannon L Maude, Theodore W Laetsch, Jochen Buechner, Susana Rives, Michael Boyer, Henrique Bittencourt, Peter Bader, Michael R Verneris, Heather E Stefanski, Gary D Myers,[...]. N Engl J Med 2018
23

Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Stephen J Schuster, Michael R Bishop, Constantine S Tam, Edmund K Waller, Peter Borchmann, Joseph P McGuirk, Ulrich Jäger, Samantha Jaglowski, Charalambos Andreadis, Jason R Westin,[...]. N Engl J Med 2019
23

Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study.
Jesus G Berdeja, Deepu Madduri, Saad Z Usmani, Andrzej Jakubowiak, Mounzer Agha, Adam D Cohen, A Keith Stewart, Parameswaran Hari, Myo Htut, Alexander Lesokhin,[...]. Lancet 2021
97
23

Current concepts in the diagnosis and management of cytokine release syndrome.
Daniel W Lee, Rebecca Gardner, David L Porter, Chrystal U Louis, Nabil Ahmed, Michael Jensen, Stephan A Grupp, Crystal L Mackall. Blood 2014
22

Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study.
Sagar Lonial, Hans C Lee, Ashraf Badros, Suzanne Trudel, Ajay K Nooka, Ajai Chari, Al-Ola Abdallah, Natalie Callander, Nikoletta Lendvai, Douglas Sborov,[...]. Lancet Oncol 2020
266
20

Chimeric antigen receptor T cells for sustained remissions in leukemia.
Shannon L Maude, Noelle Frey, Pamela A Shaw, Richard Aplenc, David M Barrett, Nancy J Bunin, Anne Chew, Vanessa E Gonzalez, Zhaohui Zheng, Simon F Lacey,[...]. N Engl J Med 2014
19

T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial.
Daniel W Lee, James N Kochenderfer, Maryalice Stetler-Stevenson, Yongzhi K Cui, Cindy Delbrook, Steven A Feldman, Terry J Fry, Rimas Orentas, Marianna Sabatino, Nirali N Shah,[...]. Lancet 2015
19

ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells.
Daniel W Lee, Bianca D Santomasso, Frederick L Locke, Armin Ghobadi, Cameron J Turtle, Jennifer N Brudno, Marcela V Maus, Jae H Park, Elena Mead, Steven Pavletic,[...]. Biol Blood Marrow Transplant 2019
831
19

CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy.
Terry J Fry, Nirali N Shah, Rimas J Orentas, Maryalice Stetler-Stevenson, Constance M Yuan, Sneha Ramakrishna, Pamela Wolters, Staci Martin, Cindy Delbrook, Bonnie Yates,[...]. Nat Med 2018
660
18

Chimeric antigen receptor T-cell therapy - assessment and management of toxicities.
Sattva S Neelapu, Sudhakar Tummala, Partow Kebriaei, William Wierda, Cristina Gutierrez, Frederick L Locke, Krishna V Komanduri, Yi Lin, Nitin Jain, Naval Daver,[...]. Nat Rev Clin Oncol 2018
18

γ-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma.
Margot J Pont, Tyler Hill, Gabriel O Cole, Joe J Abbott, Jessica Kelliher, Alexander I Salter, Michael Hudecek, Melissa L Comstock, Anusha Rajan, Bharvin K R Patel,[...]. Blood 2019
112
17

Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy.
Ujjawal H Gandhi, Robert F Cornell, Arjun Lakshman, Zhubin J Gahvari, Elizabeth McGehee, Megan H Jagosky, Ridhi Gupta, William Varnado, Mark A Fiala, Saurabh Chhabra,[...]. Leukemia 2019
182
17

γ-Secretase directly sheds the survival receptor BCMA from plasma cells.
Sarah A Laurent, Franziska S Hoffmann, Peer-Hendrik Kuhn, Qingyu Cheng, Yuanyuan Chu, Marc Schmidt-Supprian, Stefanie M Hauck, Elisabeth Schuh, Markus Krumbholz, Heike Rübsamen,[...]. Nat Commun 2015
167
16

GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells.
Eric L Smith, Kim Harrington, Mette Staehr, Reed Masakayan, Jon Jones, Thomas J Long, Khong Y Ng, Majid Ghoddusi, Terence J Purdon, Xiuyan Wang,[...]. Sci Transl Med 2019
113
16

Effective Targeting of Multiple B-Cell Maturation Antigen-Expressing Hematological Malignances by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells.
Kevin M Friedman, Tracy E Garrett, John W Evans, Holly M Horton, Howard J Latimer, Stacie L Seidel, Christopher J Horvath, Richard A Morgan. Hum Gene Ther 2018
96
16

CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients.
Cameron J Turtle, Laïla-Aïcha Hanafi, Carolina Berger, Theodore A Gooley, Sindhu Cherian, Michael Hudecek, Daniel Sommermeyer, Katherine Melville, Barbara Pender, Tanya M Budiarto,[...]. J Clin Invest 2016
16

Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial.
Frederick L Locke, Armin Ghobadi, Caron A Jacobson, David B Miklos, Lazaros J Lekakis, Olalekan O Oluwole, Yi Lin, Ira Braunschweig, Brian T Hill, John M Timmerman,[...]. Lancet Oncol 2019
807
15

Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma.
Yu-Tzu Tai, Patrick A Mayes, Chirag Acharya, Mike Y Zhong, Michele Cea, Antonia Cagnetta, Jenny Craigen, John Yates, Louise Gliddon, William Fieles,[...]. Blood 2014
261
15

Anti-BCMA chimeric antigen receptors with fully human heavy-chain-only antigen recognition domains.
Norris Lam, Nathan D Trinklein, Benjamin Buelow, George H Patterson, Namrata Ojha, James N Kochenderfer. Nat Commun 2020
44
34

BCMA is essential for the survival of long-lived bone marrow plasma cells.
Brian P O'Connor, Vanitha S Raman, Loren D Erickson, W James Cook, Lehn K Weaver, Cory Ahonen, Ling-Li Lin, George T Mantchev, Richard J Bram, Randolph J Noelle. J Exp Med 2004
692
15

International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.
S Vincent Rajkumar, Meletios A Dimopoulos, Antonio Palumbo, Joan Blade, Giampaolo Merlini, María-Victoria Mateos, Shaji Kumar, Jens Hillengass, Efstathios Kastritis, Paul Richardson,[...]. Lancet Oncol 2014
15

Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia.
Jae H Park, Isabelle Rivière, Mithat Gonen, Xiuyan Wang, Brigitte Sénéchal, Kevin J Curran, Craig Sauter, Yongzeng Wang, Bianca Santomasso, Elena Mead,[...]. N Engl J Med 2018
14

Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma.
Alfred L Garfall, Marcela V Maus, Wei-Ting Hwang, Simon F Lacey, Yolanda D Mahnke, J Joseph Melenhorst, Zhaohui Zheng, Dan T Vogl, Adam D Cohen, Brendan M Weiss,[...]. N Engl J Med 2015
399
14

Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma.
Antonio Palumbo, Asher Chanan-Khan, Katja Weisel, Ajay K Nooka, Tamas Masszi, Meral Beksac, Ivan Spicka, Vania Hungria, Markus Munder, Maria V Mateos,[...]. N Engl J Med 2016
896
14

Anti-B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple Myeloma.
Max S Topp, Johannes Duell, Gerhard Zugmaier, Michel Attal, Philippe Moreau, Christian Langer, Jan Krönke, Thierry Facon, Alexey V Salnikov, Robin Lesley,[...]. J Clin Oncol 2020
138
14

Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells.
Cameron J Turtle, Laïla-Aïcha Hanafi, Carolina Berger, Michael Hudecek, Barbara Pender, Emily Robinson, Reed Hawkins, Colette Chaney, Sindhu Cherian, Xueyan Chen,[...]. Sci Transl Med 2016
601
14

Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival.
Anne J Novak, Jaime R Darce, Bonnie K Arendt, Brandon Harder, Kathy Henderson, Wayne Kindsvogel, Jane A Gross, Philip R Greipp, Diane F Jelinek. Blood 2004
356
14

Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia.
David L Porter, Wei-Ting Hwang, Noelle V Frey, Simon F Lacey, Pamela A Shaw, Alison W Loren, Adam Bagg, Katherine T Marcucci, Angela Shen, Vanessa Gonzalez,[...]. Sci Transl Med 2015
13

4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors.
Adrienne H Long, Waleed M Haso, Jack F Shern, Kelsey M Wanhainen, Meera Murgai, Maria Ingaramo, Jillian P Smith, Alec J Walker, M Eric Kohler, Vikas R Venkateshwara,[...]. Nat Med 2015
809
13

Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia.
Marco L Davila, Isabelle Riviere, Xiuyan Wang, Shirley Bartido, Jae Park, Kevin Curran, Stephen S Chung, Jolanta Stefanski, Oriana Borquez-Ojeda, Malgorzata Olszewska,[...]. Sci Transl Med 2014
13

Anti-BCMA CAR T-cell therapy in multiple myeloma: can we do better?
Mattia D'Agostino, Noopur Raje. Leukemia 2020
71
18


Targeting B-cell maturation antigen in multiple myeloma.
Yu-Tzu Tai, Kenneth C Anderson. Immunotherapy 2015
106
13

Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma.
Alfred L Garfall, Edward A Stadtmauer, Wei-Ting Hwang, Simon F Lacey, Jan Joseph Melenhorst, Maria Krevvata, Martin P Carroll, William H Matsui, Qiuju Wang, Madhav V Dhodapkar,[...]. JCI Insight 2018
86
15


KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma.
Michael Wang, Javier Munoz, Andre Goy, Frederick L Locke, Caron A Jacobson, Brian T Hill, John M Timmerman, Houston Holmes, Samantha Jaglowski, Ian W Flinn,[...]. N Engl J Med 2020
447
13

CAR T cell therapies for patients with multiple myeloma.
Lekha Mikkilineni, James N Kochenderfer. Nat Rev Clin Oncol 2021
60
21

A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed/refractory multiple myeloma.
Di Wang, Jue Wang, Guang Hu, Wen Wang, Yi Xiao, Haodong Cai, Lijun Jiang, Li Meng, Yongkun Yang, Xiaoxi Zhou,[...]. Blood 2021
30
43

CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape.
Mohamad Hamieh, Anton Dobrin, Annalisa Cabriolu, Sjoukje J C van der Stegen, Theodoros Giavridis, Jorge Mansilla-Soto, Justin Eyquem, Zeguo Zhao, Benjamin M Whitlock, Matthew M Miele,[...]. Nature 2019
193
12

Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo.
Michael C Milone, Jonathan D Fish, Carmine Carpenito, Richard G Carroll, Gwendolyn K Binder, David Teachey, Minu Samanta, Mehdi Lakhal, Brian Gloss, Gwenn Danet-Desnoyers,[...]. Mol Ther 2009
740
12

APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment.
Yu-Tzu Tai, Chirag Acharya, Gang An, Michele Moschetta, Mike Y Zhong, Xiaoyan Feng, Michele Cea, Antonia Cagnetta, Kenneth Wen, Hans van Eenennaam,[...]. Blood 2016
162
12


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.